Loading clinical trials...

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY | Clinical Trials | Clareo Health

WITHDRAWNPHASE2/PHASE3

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

NCT04575064•Professor Dr. Bernd Mühlbauer

View on ClinicalTrials.gov

Summary

This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients 18 years and older
•Current SARS-CoV-2 infection
•Admitted to the hospital ward or the ICU due to COVID-19
•SpO2 \<= 94% on room air OR oxygen demand OR breathing support
•Written informed consent obtained

Exclusion Criteria

•Patient's non-consent or inability to informed consent
•Pregnant or breastfeeding women.
•Subjects pretreated with one of the study drugs in the past 29 days
•Anticipated transfer within 72 hours to a non-study hospital
•Severe co-morbidity with life expectancy \< 3 months
•AST or ALT \> 5 times the upper limit of normal
•Stage 4 severe chronic kidney disease or requiring dialysis
•Contraindications and known intolerance to any of the study drugs
•Subjects participating in a potentially confounding drug or device trial
•Any reason why the patient should not participate (investigator's opinion)

Locations (4)

Gesundheit Nord gGmbH

Bremen, Germany

Universitätsklinikum Gießen

Giessen, Germany

Medizinische Hochschule Hannover (MHH)

Hanover, Germany

Technische Universität München (TUM)

München, Germany

Key Dates

Start Date

June 29, 2020

Primary Completion Date

March 1, 2022

Completion Date

November 1, 2022

Last Updated

October 9, 2024

Conditions

SARS-CoV-2 InfectionCOVID-19Moderate and Severe COVID-19

Interventions

Standard of Care (SoC)

OTHER

Remdesivir

DRUG

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

NCT06082518

Post COVID-19 ConditionPost-COVID-19 Syndrome+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

Inclusion Criteria

Exclusion Criteria

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate